AstraZeneca announces that Datroway (datopotamab deruxtecan), developed with Daiichi Sankyo, has demonstrated a significant improvement in overall survival and progression-free survival compared to chemotherapy as first-line treatment for metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy.
A phase III trial showed a median gain of 5 months in overall survival (23.7 months vs. 18.7 months) and a 43% reduction in the risk of progression or death (from 10.8 months vs. 5.6 months).
According to Rebecca Dent, professor and principal investigator, the treatment significantly prolonged the lives of patients and nearly doubled their progression-free survival.
AstraZeneca believes that these results pave the way for an alternative to first-line chemotherapy and reinforce the potential of Datroway in future therapeutic combinations.
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (5.8%).
Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
